Condition: Bladder Cancer · Sponsor: National Cancer Center, Korea
The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.
This description comes directly from the study's public registry record.
Ho Kyung Seo, MD · 82-31-920-1678 · seohk@ncc.re.kr
Eui Hyun Jung, Ph.D · 82-31-920-2451 · jeh0315@ncc.re.kr
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang-si, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06388720